Trial Profile

A Phase Ib/IIa study of AZD2014 in combination with Selumetinib in patients with advanced cancers

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 02 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Selumetinib (Primary) ; Vistusertib (Primary)
Indications Advanced breast cancer; Non-small cell lung cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
Focus Therapeutic Use
Acronyms TORCMEK

Most Recent Events

02 Feb 2022 According to ClinicalTrials.gov record, the recruitment status of this study is unknown because the information has not been verified recently(Last verified 24 February 2020).
24 Feb 2020 Planned End Date changed from 1 Jul 2019 to 1 Mar 2020.
24 Feb 2020 Planned primary completion date changed from 1 Jul 2019 to 1 Mar 2020.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com